 DURHAM, N.C., Sept. 20, 2021 GLOBE NEWSWIRE -- Bioventus Inc., Nasdaq: BVS Bioventus or the Company, a leader in innovations for active healing, announced that the American Academy of Orthopaedic Surgeons AAOS recently released updated clinical practice guidelines CPG indicating that high molecular weight cross-linked hyaluronic treatments, including Bioventus treatment DUROLANE, showed statistically significant improvement in certain knee osteoarthritis OA patients. The recommendation follows a review of 28 studies assessing intra-articular hyaluronic acid HA injections when compared to controls. 